Roches Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors

Roche today announced full results from the phase III HAVEN 3 study evaluating Hemlibra emicizumab prophylaxis administered every week or every two weeks in people with haemophilia A without fa…
Read the full story: Bioportfolio Latest News